NeurogesX, Inc. (Nasdaq:NGSX) a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking to expand the label for Qutenza(R) (capsaicin) 8% patch to include an indication for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN), also known as HIV-associated neuropathy (HIV-AN) and HIV-distal sensory polyneuropathy (HIV-DSP).

NeurogesX, Inc. is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions.

To read more at : http://doubleinstocks.com/?p=18513